
RNAC Stock Forecast & Price Target
RNAC Analyst Ratings
Bulls say
Cartesian Therapeutics Inc. demonstrates a positive outlook due to its innovative mRNA-based cell therapy technology, which shows promising efficacy in treating autoimmune diseases such as systemic lupus erythematosus and dermatomyositis. The recent Phase 2b data indicated sustained and clinically meaningful improvements in patient outcomes, with significant reductions in multiple interferon-linked cytokines and a favorable safety profile compared to traditional therapies. Additionally, the differentiated mechanisms of Descartes-08 suggest greater potential for broader patient uptake and long-term treatment success, supporting a strong market position for the company's product offerings.
Bears say
Cartesian Therapeutics Inc. has experienced a decline in cash reserves from $162.1 million to $145.1 million between Q2 2025 and Q3 2025, indicating increased operational spending related to its Phase 3 MG program. Despite the company's cash position reportedly allowing operations to continue into mid-2027, investor sentiment appears to undervalue the firm's Phase 3 program, given its current market capitalization of under $200 million and an effective enterprise value of approximately $50 million. Furthermore, the company faces challenges with existing treatment options in the autoimmune disease space, which may hinder the uptake of its therapies amid high patient burden and insufficient capture of a significant patient population not currently receiving treatment.
This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNAC Analyst Forecast & Price Prediction
Start investing in RNAC
Order type
Buy in
Order amount
Est. shares
0 shares